1. Home
  2. TNDM vs DNA Comparison

TNDM vs DNA Comparison

Compare TNDM & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNDM
  • DNA
  • Stock Information
  • Founded
  • TNDM 2006
  • DNA 2008
  • Country
  • TNDM United States
  • DNA United States
  • Employees
  • TNDM N/A
  • DNA N/A
  • Industry
  • TNDM Medical/Dental Instruments
  • DNA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TNDM Health Care
  • DNA Health Care
  • Exchange
  • TNDM Nasdaq
  • DNA Nasdaq
  • Market Cap
  • TNDM 1.1B
  • DNA 895.1M
  • IPO Year
  • TNDM 2013
  • DNA N/A
  • Fundamental
  • Price
  • TNDM $15.50
  • DNA $13.64
  • Analyst Decision
  • TNDM Buy
  • DNA Strong Sell
  • Analyst Count
  • TNDM 16
  • DNA 1
  • Target Price
  • TNDM $23.25
  • DNA $9.00
  • AVG Volume (30 Days)
  • TNDM 1.9M
  • DNA 1.8M
  • Earning Date
  • TNDM 11-06-2025
  • DNA 11-11-2025
  • Dividend Yield
  • TNDM N/A
  • DNA N/A
  • EPS Growth
  • TNDM N/A
  • DNA N/A
  • EPS
  • TNDM N/A
  • DNA N/A
  • Revenue
  • TNDM $1,001,719,000.00
  • DNA $230,815,000.00
  • Revenue This Year
  • TNDM $8.27
  • DNA N/A
  • Revenue Next Year
  • TNDM $9.72
  • DNA $14.41
  • P/E Ratio
  • TNDM N/A
  • DNA N/A
  • Revenue Growth
  • TNDM 25.84
  • DNA 25.21
  • 52 Week Low
  • TNDM $9.98
  • DNA $5.00
  • 52 Week High
  • TNDM $38.28
  • DNA $17.58
  • Technical
  • Relative Strength Index (RSI)
  • TNDM 62.48
  • DNA 49.81
  • Support Level
  • TNDM $14.53
  • DNA $13.16
  • Resistance Level
  • TNDM $15.57
  • DNA $16.50
  • Average True Range (ATR)
  • TNDM 0.86
  • DNA 1.53
  • MACD
  • TNDM 0.14
  • DNA -0.16
  • Stochastic Oscillator
  • TNDM 92.45
  • DNA 23.35

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Share on Social Networks: